166 related articles for article (PubMed ID: 28435296)
1. Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date.
Levin PA; Dowell JE
Onco Targets Ther; 2017; 10():2057-2066. PubMed ID: 28435296
[TBL] [Abstract][Full Text] [Related]
2. LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma.
Scagliotti GV; Gaafar R; Nowak AK; Reck M; Tsao AS; van Meerbeeck J; Vogelzang NJ; Nakano T; von Wangenheim U; Velema D; Morsli N; Popat S
Clin Lung Cancer; 2017 Sep; 18(5):589-593. PubMed ID: 28690011
[TBL] [Abstract][Full Text] [Related]
3. The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.
Li Q; Yano S; Ogino H; Wang W; Uehara H; Nishioka Y; Sone S
Clin Cancer Res; 2007 Oct; 13(19):5918-25. PubMed ID: 17908988
[TBL] [Abstract][Full Text] [Related]
4. Malignant peritoneal mesothelioma: a review.
Broeckx G; Pauwels P
Transl Lung Cancer Res; 2018 Oct; 7(5):537-542. PubMed ID: 30450291
[TBL] [Abstract][Full Text] [Related]
5. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment.
Gounant V; Brosseau S; Zalcman G
Ther Adv Med Oncol; 2021; 13():17588359211061956. PubMed ID: 34917175
[TBL] [Abstract][Full Text] [Related]
7. Pemetrexed (Alimta): improving outcomes in malignant pleural mesothelioma.
Budde LS; Hanna NH
Expert Rev Anticancer Ther; 2004 Jun; 4(3):361-8. PubMed ID: 15161435
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients.
Lin RC; Kirschner MB; Cheng YY; van Zandwijk N; Reid G
Genom Data; 2016 Sep; 9():44-9. PubMed ID: 27408810
[TBL] [Abstract][Full Text] [Related]
9. [Malignant pleural mesothelioma: rare and aggressive but with new therapeutic perspectives].
Brosseau S; Naltet C; Gounant V; Zalcman G
Rev Prat; 2016 Feb; 66(2):191-197. PubMed ID: 30512336
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy treatment in malignant pleural mesothelioma: a difficult history.
Cinausero M; Rihawi K; Sperandi F; Melotti B; Ardizzoni A
J Thorac Dis; 2018 Jan; 10(Suppl 2):S304-S310. PubMed ID: 29507800
[TBL] [Abstract][Full Text] [Related]
11. Malignant pleural mesothelioma.
Chen SE; Pace MB
Am J Health Syst Pharm; 2012 Mar; 69(5):377-85. PubMed ID: 22345416
[TBL] [Abstract][Full Text] [Related]
12. E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles.
Ikuta K; Yano S; Trung VT; Hanibuchi M; Goto H; Li Q; Wang W; Yamada T; Ogino H; Kakiuchi S; Uehara H; Sekido Y; Uenaka T; Nishioka Y; Sone S
Clin Cancer Res; 2009 Dec; 15(23):7229-37. PubMed ID: 19934291
[TBL] [Abstract][Full Text] [Related]
13. Pemetrexed in malignant pleural mesothelioma.
Hazarika M; White RM; Booth BP; Wang YC; Ham DY; Liang CY; Rahman A; Gobburu JV; Li N; Sridhara R; Morse DE; Lostritto R; Garvey P; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Feb; 11(3):982-92. PubMed ID: 15709163
[TBL] [Abstract][Full Text] [Related]
14. Molecular targets in malignant pleural mesothelioma treatment.
Pasello G; Favaretto A
Curr Drug Targets; 2009 Dec; 10(12):1235-44. PubMed ID: 19909234
[TBL] [Abstract][Full Text] [Related]
15. Current chemotherapy strategies in malignant pleural mesothelioma.
de Gooijer CJ; Baas P; Burgers JA
Transl Lung Cancer Res; 2018 Oct; 7(5):574-583. PubMed ID: 30450296
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogeneic Strategies in Mesothelioma.
Nowak AK; Brosseau S; Cook A; Zalcman G
Front Oncol; 2020; 10():126. PubMed ID: 32133285
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma.
Moriya M; Yamada T; Tamura M; Ishikawa D; Hoda MA; Matsumoto I; Klepetko W; Oda M; Yano S; Watanabe G
Oncol Rep; 2014 Mar; 31(3):1109-15. PubMed ID: 24378576
[TBL] [Abstract][Full Text] [Related]
18. SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma.
Iwahori K; Serada S; Fujimoto M; Ripley B; Nomura S; Mizuguchi H; Shimada K; Takahashi T; Kawase I; Kishimoto T; Naka T
Int J Cancer; 2013 Jan; 132(2):459-71. PubMed ID: 22532243
[TBL] [Abstract][Full Text] [Related]
19. Novel approaches for the treatment of unresectable malignant pleural mesothelioma: A focus on immunotherapy and target therapy (Review).
Rijavec E; Biello F; Barletta G; Dellepiane C; Genova C
Mol Clin Oncol; 2022 Apr; 16(4):89. PubMed ID: 35251640
[TBL] [Abstract][Full Text] [Related]
20. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion.
Du N; Li X; Li F; Zhao H; Fan Z; Ma J; Fu Y; Kang H
Oncol Rep; 2013 Jun; 29(6):2332-40. PubMed ID: 23525453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
